ALIGOS THERAPEUTICS, INC.

(ALGS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aligos Therapeutics Shares Rise 6% on Merck Collaboration Agreement

01/11/2022 | 12:39pm EDT

By Chris Wack

Aligos Therapeutics Inc. shares were up 6% to $3.94 after the company said it has expanded its ongoing collaboration with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis.

The stock hit its 52-week low of $3.55 on Monday, when it closed down 5%.

Under the original agreement, Merck and Aligos committed to applying Aligos' oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a certain undisclosed non-alcoholic steatohepatitis target and up to one additional target of interest in the cardiometabolic/fibrosis space.

That agreement has now been expanded to include the in-license by Merck of an early-stage program with respect to a second undisclosed NASH target on which Aligos has previously been working independently and separately from Merck. In addition, under this expanded arrangement, Merck has the ability of adding an additional third target of interest in the cardiometabolic/fibrosis space to the collaboration.

Under the expanded agreement, Aligos will receive a payment from Merck for the in-license of the program directed at a second undisclosed NASH target. Aligos will also receive an additional payment upon designation of a third target for the collaboration.

With respect to each target in the collaboration, Aligos will be eligible to receive up to $460 million in development and commercialization milestones as well as tiered royalties on sales. Aligos is primarily responsible for designing, synthesizing and evaluating the oligonucleotide candidates and delivering optimized lead molecules. Thereafter, Merck is responsible for subsequent research, clinical development and commercialization.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

01-11-22 1238ET

Stocks mentioned in the article
ChangeLast1st jan.
ALIGOS THERAPEUTICS, INC. -1.82% 1.08 Delayed Quote.-90.90%
MERCK & CO., INC. 1.59% 93.55 Delayed Quote.22.06%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
All news about ALIGOS THERAPEUTICS, INC.
05/17Top Premarket Gainers
MT
05/05SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to..
MT
05/04Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q1 Loss $-0.84, vs. Street Est of $-0.7..
MT
05/04ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/04Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/04Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial R..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
AQ
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
CI
04/27Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
AQ
More news
Analyst Recommendations on ALIGOS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 2,58 M - -
Net income 2022 -118 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,40x
Yield 2022 -
Capitalization 46,1 M 46,1 M -
Capi. / Sales 2022 17,9x
Capi. / Sales 2023 -
Nbr of Employees 95
Free-Float 77,2%
Chart ALIGOS THERAPEUTICS, INC.
Duration : Period :
Aligos Therapeutics, Inc. Technical Analysis Chart | ALGS | US01626L1052 | MarketScreener
Technical analysis trends ALIGOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,08 $
Average target price 4,70 $
Spread / Average Target 335%
EPS Revisions
Managers and Directors
Lawrence M. Blatt Chairman & Chief Executive Officer
Leonid N. Beigelman President & Director
Lesley Ann Calhoun Chief Financial Officer & Executive Vice President
Julian A. Symons Chief Scientific Officer & Executive VP
John Fry Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ALIGOS THERAPEUTICS, INC.-90.90%46
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567